The ProVIDE study is a prospective, randomized, double-blind, sham controlled study evaluating the safety and effectiveness of the ProVee® Urethral Expander System for the treatment of lower urinary ...

More than 40 million American men will be affected by benign prostatic hyperplasia (BPH), commonly known as an enlarged ...

Optilume system improves urinary flow and reduces urinary symptoms without affecting sexual function in men with benign ...

LAS VEGAS -- A novel, non-ablative intervention for lower urinary tract symptoms (LUTS) produced rapid, durable symptom ...

Medical device company Zenflow has reported that its Spring System demonstrated durable benefits three years post-placement ...

The responder rate, calculated as the proportion of subjects with ≥ 30% improvement in IPSS, was 74% at 36 months, similar to 75% at 12 months and 70% at 24 months. No deterioration in erectile or ...

Rivermark Medical, a urology-focused medical device company committed to redefining benign prostatic hyperplasia (BPH) ...